论文部分内容阅读
目的观察平眩胶囊治疗肝阳上亢型眩晕症患者的疗效及安全性。方法选取肝阳上亢型眩晕症患者60例作为研究对象,随机分为治疗组和对照组,各30例。治疗组予以平眩胶囊,3粒/次,3次/d,对照组给予盐酸氟桂利嗪胶囊,5 mg/次,每晚1次口服,两组治疗疗程均为14天。两组治疗前后均进行TCD、血流变检测,并对患者眩晕发作持续时间和次数进行比较。结果两组眩晕发作次数和持续时间均有下降,TCD血流速度均有改善,血粘度指标均有好转,与本组治疗前相比较,差异均有统计学意义(P<0.05)。平眩胶囊在各项指标改善方面作用明显,与盐酸氟桂利嗪胶囊比较,差异有统计学意义(P<0.05)。两组患者血、尿、粪常规、肝、肾功能及心电图等指标治疗前与治疗后均正常。结论平眩胶囊在治疗肝阳上亢型眩晕症患者疗效肯定。
Objective To observe the efficacy and safety of PingDuan Capsule in treating patients with vertigo of liver-yang hyperactivity. Methods Sixty patients with hyperactivity of liver-yang hyperactivity were selected as study subjects and randomly divided into treatment group and control group, with 30 cases in each group. The treatment group was given PingDuan capsule, 3 capsules / time, 3 times / d, the control group was given flunarizine hydrochloride capsule, 5 mg / time, once a night orally, the two groups were treated for 14 days. Before and after treatment, TCD and blood rheology were measured in both groups, and the duration and number of vertigo episodes were compared. Results Both the number of episodes of vertigo and the duration of the two groups decreased, the blood flow velocity of TCD improved and the indexes of blood viscosity improved. Compared with those before treatment, the differences were statistically significant (P <0.05). PingDuan Capsule has obvious effect in improving various indexes. Compared with Flunarizine Hydrochloride Capsule, the difference is statistically significant (P <0.05). Two groups of patients with blood, urine, fecal routine, liver, kidney function and ECG and other indicators before and after treatment were normal. Conclusions PingDuan Capsule is effective in treating patients with vertigo of liver-yang hyperactivity.